A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients

• Register: EUCTR
• Last refreshed on: 4 January 2022
• Main ID: EUCTR2016-003456-70-AT
• Date of registration: 16/11/2017
• Prospective Registration: Yes
• Primary sponsor: Sunovion Pharmaceuticals Inc.
• Public title: A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphine in Parkinson’s Disease patients
• Scientific title: An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations
• Date of first enrolment: 04/01/2018
• Target sample size: 106
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003456-70
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: yes; Single blind: no; Double blind: no; Parallel group: no; Cross over: yes; Other: no; If controlled, specify comparator, Other Medicinial Product: yes; Placebo: no; Other: no; Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Austria, France, Germany, Italy, Spain, United Kingdom

Contacts

• Name: Eniko Dalanics
• Affiliation: Syneos Health / INC Research Hungary Kft.

• Name: Eniko Dalanics
• Affiliation: Syneos Health / INC Research Hungary Kft.

Key inclusion & exclusion criteria

Inclusion criteria:
1 The subject (and caregiver, if applicable) must be fully informed of and
understand the objectives, procedures, and possible benefits and risks of
the study, and give written informed consent prior to performing any
study-related activities.
2 Male or female = 18 years of age.
3 Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank
Criteria (excluding the "more than one affected relative" criterion).
4 Clinically meaningful response to levodopa (L-Dopa), as determined by
the Investigator.
5 Subjects at Screening must demonstrate an adequate L-Dopa response
on the MDS-UPDRS Part III in the "ON" state compared to the MDS
UPDRS
Part III in the "OFF" state and on the Hoehn and Yahr, as
determined during the review by Enrollment Adjudication Committee
(EAC), Sponsor, and Medical Monitor.
6 Receiving stable doses of L-Dopa/carbidopa and/or L-Dopa/
benserazide and/or L-Dopa/carbidopa/entacapone (immediate or
chronic release) administered at least 4 times per day OR RytaryTM
administered at least 3 times per day for at least 4 weeks before the
Initial Screening Visit (SV1). Adjunctive PD medication regimens are
permitted but must be maintained at a stable dose for at least 4 weeks
prior to SV1 with the exception of monoamine oxidase B (MAO-B)
inhibitors, which must be maintained at a stable level for at least 8
weeks prior to SV1. Use of Madopar PRN in the 4 weeks prior to screening is permitted. Current use of a sc apomorphine by injection at the time of screening is permitted.

7 No planned medication change(s) or surgical intervention anticipated
during the course of study.
8 Subjects must experience at least one well defined "OFF" episode per
day and have a total daily "OFF" time duration of > 2 hours during the
waking day, based on judgment of physician and subject self
assessment.
9 Subject must have predictable morning "OFF" periods, based on
judgment of physician and subject self-assessment.
10 Subject, and where appropriate caregiver, must be trained in
completing the home dosing diaries and able to recognize "ON" and
"OFF" states.
11 Stage III or less on the modified Hoehn and Yahr scale in the "ON"
state.
12 Mini–Mental State Examination (MMSE) score > 25.
13 Female subject of childbearing potential and male subject with
female partner of childbearing potential must agree to either remain
abstinent or use adequate and reliable contraception (see Section 10.4.1
for additional information on acceptable methods of birth control)
throughout the study and for at least 7 days after the last dose of study
drug has been taken. Note: Continued use of adequate and reliable
contraception is recommended through 30 days after study completion.
14 Willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study-related procedures to complete the
study.
15 Must be approved as a satisfactory candidate by the Enrollment
Adjudication Committee (EAC), Medical Monitor, and Sponsor.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 64
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 42

Exclusion criteria:
1 Atypical or secondary parkinsonism.
2 Major focal brain disorders including malignancy or stroke.
3 Prior treatment with any of the following: a neurosurgical procedure
for PD; continuous subcutaneous (sc) apomorphine infusion; sc
apomorphine injection; Duodopa/Duopa; or APL-130277.
4. Subjects who have permanently stopped use of s.c. apomorphine
(injection).
5 Female who is pregnant or lactating.
6 Participation in an interventional clinical study and/or receipt of any
investigational (ie, unapproved) medication within 30 days prior to SV1.
7 Currently taking selective 5HT3 antagonists (ie, ondansetron,
granisetron, dolasetron, palonosetron, alosetron), dopamine antagonists
(excluding quetiapine or clozapine) or dopamine depleting agents.
Subjects receiving anti-depressants must be on a stable daily dose for at
least 8 weeks prior to SV1.
8 current diagnosis or history of substance abuse (excluding nicotine
and caffeine) or alcohol abuse (in the opinion of the investigator) < 6
months prior to SV1.
9 positive urine drug screen result. NOTE: Benzodiazepines, opiates, and
oxycodone will be allowed provided the subject has been on a stable
dose for 4 weeks prior to SV1, provided the subject has a valid
prescription. Cotinine is not exclusionary.
10 The recreational use of cannabinoids and hallucinogenic(including
formulations of CBD) and hallucinogenics are excluded, as well any use
of a sublingual formulation of any drug.
11 history of malignancy within 5 years prior to SV1, except for
adequately treated basal cell or squamous cell skin cancer or in situ
cervical cancer.
12 clinically significant abnormality on screening evaluation including
physical examination, vital signs, electrocardiogram (ECG), or laboratory
tests that the Investigator considers to be inappropriate to allow
participation in the study.
13 screening laboratory test results of: BUN value = 1.5 times the upper
limit of normal (ULN) for the reference range; serum creatinine > 1.5
times the ULN for the reference range; or ALT or AST value = 2 times the
ULN for the reference laboratory.
14 random (non-fasting) screening glucose of = 200 mg/dL (11.1
mmol/L) or HbA1c > 7.0%.
15 Subjects with type 1 diabetes, or insulin-dependent diabetics are
excluded. Subjects with type 2 diabetes are eligible for study inclusion if
the following conditions are met:
• Subject's screening glucose is < 200 mg/dL (11.1 mmol/L). Note:
Subjects with random (non-fasting) blood glucose at screening = 200
mg/dL (11.1 mmol/L) must be retested in a fasted state; and
• Subject's HbA1c = 7.0%; and
• If the subject is currently being treated with oral anti-diabetic
medication(s), the dose must have been stable for at least 4 weeks prior
to SV1. Such medication may be adjusted or discontinued during the
study, as clinically indicated.
16 The subject's screening ECG results of corrected QT interval using
Fridericia's formula (QTcF) = 450 msec for male subjects or = 470 msec
for female subjects. Eligibility will be based on the core laboratory ECG
interpretation report.
17 positive screening laboratory test result for HIV.
18 positive screening laboratory test result for hepatitis B surface
antigen or hepatitis C antibodies and has liver function test results at
screening above the ULN for the reference laboratory.
19 any other medical disorder that, in the opinion of the Investigator,
could interfere with the subject's participation in the stud

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF episodes")
MedDRA version: 22.1 Level: LLT Classification code 10034006 Term: Parkinson's disease aggravated System Organ Class: 100000004852

Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Intervention(s)

Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use

Trade Name: APO-go
Product Name: s.c. apomorphine
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-

Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use

Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomorphine hydrochloride
CAS Number: 41372-20-7
Current Sponsor code: APL-130277
Other descriptive name: APOMORPHINE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Sublingual film
Route of administration of the placebo: Sublingual use

Product Name: Apomorphine hydrochloride
Product Code: APL-130277
Pharmaceutical Form: Sublingual film
INN or Proposed INN: Apomor

Primary Outcome(s)

Main Objective: The primary objective is to demonstrate the efficacy of sublingual (sl)
APL-130277 compared to subcutaneous (sc) apomorphine as a
treatment of "OFF" episodes in subjects with Parkinson's Disease (PD)
as measured by the change from pre-dose to 90 minutes post-dose in
Movement Disorder Society Unified Parkinson's Disease Rating Scale
(MDS-UPDRS) Part III score.

Secondary Objective: The secondary objectives are to demonstrate the efficacy of sublingual
(sl) APL-130277 compared to subcutaneous (sc) apomorphine as a
treatment of "OFF" episodes in subjects with Parkinson's Disease (PD)
as measured by:
• Durability of effect, defined as Investigator confirmed full "ON" within
30 minutes post-dose and at 90 minutes post-dose;
• Subject preference for APL-130277 treatment (either somewhat or
definitely prefer APL) as recorded for question 9 of the TPQ. This
assessment is scheduled to be performed after the subject has
completed both APL-130277 and sc apomorphine treatment regimens;
• Subject confirmed durability of effect, defined as subject confirmed full
"ON" within 30 minutes post-dose and at 90 minutes post-dose;
• Patient Global Impression of Change of "OFF" episodes (PGI-C).

Timepoint(s) of evaluation of this end point: The change from pre-dose to 90 minutes post-dose in MDS-UPDRS Part
III score after 4 weeks of dosing in each crossover period (assessed by
the blinded-rater in-clinic at V3 and V6 of PART B).

Primary end point(s): The primary efficacy variable is the change from pre-dose to 90 minutes
post-dose in MDS-UPDRS Part III score after 4 weeks of dosing in each
crossover period (assessed by the blinded-rater in-clinic at V3 and V6 of
PART B).

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: Refer to section E.5.2

Secondary end point(s): 1 Durability of effect, defined as an Investigator confirmed full "ON"
within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks
of dosing in each crossover period (assessed by the blinded-rater inclinic
at V3 and V6 of PART B).
2 Subject preference for APL-130277 treatment (either somewhat or
definitely prefer APL-130277) for treatment regimen as measured by the Subject
Preference Visual Analog Scale (VAS) after the subject has completed
both APL-130277 and sc apomorphine treatment regimens (assessed inclinic
at V6 of PART B).
3 Subject confirmed durability of effect, defined as subject confirmed full
"ON" within 30 minutes post-dose and at 90 minutes post-dose, after 4
weeks of dosing in each crossover period (assessed in-clinic at V3 and
V6 of PART B).
4 Patient Global Impression of Change (PGI-C): Subject improvement of
"OFF" episodes, defined as very much better, much better or a little
better after 4 weeks of dosing in each crossover period (assessed inclinic
at V3 and V6 of PART B).
Other Efficacy Endpoints (PART B):
XML File Identifier: BbpgehOD9Gv16cUkdq+anMrEG7Y=
Page 32/44
Other efficacy variables will include analysis of: Clinical Global
Impression of Improvement (CGI-I), MDS-UPDRS – Parts I, II, III and
IV Score, Time to Full and Partial "ON", Expanded Home Dosing Diaries
including percent of "ON" episodes without troublesome dyskinesia
based on the 3 consecutive days prior to V2, V3, V5, and V6, dyskinesia
questionnaire, Parkinson's Disease Questionnaire-39 (PDQ-39) Total
Index Score and subscale scores, European Quality of Life – 5
Dimensions (EQ-5D-5L), and Ease of Use questionnaire. Methodology concerning the analysis of these
variables will be provided in the Statistical Analysis Plan (SAP).
Safety Endpoints:
Evaluation of safety and tolerability of APL-130277 compared to sc
apomorphine as measured by AEs, physical examination including
assessment of oropharyngeal AEs and injection-site related AEs, 12-lead
ECGs, vital signs including OH, clinical laboratory tests, and C-SSRS and
QUIP-RS assessments.
Pharmacokinetic Endpoints:
Pharmacokinetic concentration-time data for apomorphine and
metabolites (apomorphine sulfate, norapomorphine, and others as
deemed necessary) will be evaluated and PK parameters (including but
not limited to Cmax, tmax, AUCt, parent-to-metabolite ratios of Cmax
and AUCt) will be estimated by noncompartmental methods from plasma
samples using actual elapsed time from dosing. Details and methodology
concerning the analysis of these variables will be provided in a separate
PK analysis plan. A separate and stand-alone PK report will be
provided.

Secondary ID(s)

2016-003456-70-GB

CTH-302

Source(s) of Monetary Support

Sunovion Pharmaceuticals Inc.

Ethics review

Status: Approved
Approval date: 07/12/2017
Contact: